Profund Advisors LLC Makes New Investment in Palvella Therapeutics, Inc. $PVLA

Profund Advisors LLC bought a new stake in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 5,813 shares of the company’s stock, valued at approximately $608,000.

Other large investors also recently added to or reduced their stakes in the company. Archer Investment Corp acquired a new position in Palvella Therapeutics during the 3rd quarter valued at about $28,000. Russell Investments Group Ltd. acquired a new position in Palvella Therapeutics during the 3rd quarter valued at about $36,000. China Universal Asset Management Co. Ltd. acquired a new position in Palvella Therapeutics during the 4th quarter valued at about $167,000. Chung Wu Investment Group LLC lifted its position in Palvella Therapeutics by 1,200.0% during the 4th quarter. Chung Wu Investment Group LLC now owns 2,600 shares of the company’s stock valued at $272,000 after purchasing an additional 2,400 shares during the period. Finally, AlphaQuest LLC acquired a new position in Palvella Therapeutics during the 3rd quarter valued at about $164,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PVLA has been the subject of a number of analyst reports. Stephens reaffirmed an “overweight” rating and set a $220.00 target price on shares of Palvella Therapeutics in a report on Thursday. HC Wainwright lifted their target price on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Chardan Capital reaffirmed a “buy” rating and set a $240.00 target price on shares of Palvella Therapeutics in a report on Thursday. TD Cowen reaffirmed a “buy” rating on shares of Palvella Therapeutics in a report on Monday, February 2nd. Finally, Mizuho lifted their target price on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $199.53.

Insider Activity at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total value of $507,592.98. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director George M. Jenkins acquired 4,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was bought at an average cost of $125.00 per share, for a total transaction of $500,000.00. Following the completion of the transaction, the director directly owned 187,171 shares in the company, valued at $23,396,375. This represents a 2.18% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 20.50% of the stock is currently owned by insiders.

Palvella Therapeutics Stock Down 1.7%

Shares of PVLA stock opened at $113.99 on Friday. Palvella Therapeutics, Inc. has a 12-month low of $20.20 and a 12-month high of $151.18. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -27.34 and a beta of -0.13. The firm has a fifty day moving average of $121.93 and a 200-day moving average of $105.45.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.30). Research analysts expect that Palvella Therapeutics, Inc. will post -5.43 earnings per share for the current year.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.